| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/02/2011 | EP2280006A1 Pharmaceutical composition for inhalation comprising an oxazole or thiazole m3 muscarinic receptor antagonist |
| 02/02/2011 | EP2280001A1 Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient |
| 02/02/2011 | EP2280000A1 Compound having npy y5 receptor antagonist activity |
| 02/02/2011 | EP2279999A1 Retinoid derivative and pharmaceutical composition and use thereof |
| 02/02/2011 | EP2279778A1 Storage-stable compositions of glycerol monoalkyl ethers |
| 02/02/2011 | EP2279777A2 Compounds and compositions as channel activating protease inhibitors |
| 02/02/2011 | EP2279759A2 Compounds and methods for 18F labeled agents |
| 02/02/2011 | EP2279751A2 Stabilisation of macrolides |
| 02/02/2011 | EP2279750A1 Aniline derivative having anti-rna viral activity |
| 02/02/2011 | EP2279743A2 ApoE mimetic agents |
| 02/02/2011 | EP2279742A2 Combinations for the treatment of immunoinflammatory disorders |
| 02/02/2011 | EP2279741A2 Caprolactams and their use as anti-inflammatory agents |
| 02/02/2011 | EP2279740A1 Transdermal preparation |
| 02/02/2011 | EP2279739A1 Donepezil-containing patch preparation and packaging thereof |
| 02/02/2011 | EP2279738A1 The use of quaternary pyridinium salts as vasoprotective agents |
| 02/02/2011 | EP2279737A1 Heterocyclic compounds that are active as beta lactamase inhibitors |
| 02/02/2011 | EP2279736A1 Microbicidal and antiparasitic compositions comprising quassinoids or quassionid-containing plant extracts |
| 02/02/2011 | EP2279735A2 Compositions comprising crystalline trans-(+/-)-delta-9-tetrahydrocannabinol |
| 02/02/2011 | EP2279734A1 Composition for preventing cardiovascular event in high-risk patient |
| 02/02/2011 | EP2279733A2 Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease |
| 02/02/2011 | EP2279732A2 Compounds and compositions for delivering active agents |
| 02/02/2011 | EP2279731A1 Improved pharmaceutical composition containing ibuprofen and codeine |
| 02/02/2011 | EP2279730A1 Medium chain fatty acids applicable as anti-microbial agents against Enterococcus sp. |
| 02/02/2011 | EP2279727A2 Nanoparticulate aripiprazole formulations |
| 02/02/2011 | EP2279713A2 Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals |
| 02/02/2011 | EP2279673A1 Compositions for lowering serum cholesterol |
| 02/02/2011 | EP2279672A1 Synergism of GOS and polyfructose |
| 02/02/2011 | EP2279671A1 Synergism of GOS and polyfructose |
| 02/02/2011 | EP2279667A1 Vegetable and marine oil or fat compositions enriched with DHA or EPA and C18 or higher fatty acid |
| 02/02/2011 | EP2279662A2 5,7,4'-trihydroxy-3',5'-dimethoxyflavone as an antibacterial agent |
| 02/02/2011 | EP2279532A2 Oxazolobenzimidazole derivatives |
| 02/02/2011 | EP2279254A1 Novel lipid formulations for nucleic acid delivery |
| 02/02/2011 | EP2279197A1 Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| 02/02/2011 | EP2279196A2 Compounds including an anti-inflammatory pharmacore and methods of use |
| 02/02/2011 | EP2279195A1 Medicinal applications of benzoic acid hydrazones synthesized on the basis of steroidal tigogenin |
| 02/02/2011 | EP2279193A1 Novel triazole derivatives, their preparation and their application in therapeutics |
| 02/02/2011 | EP2279191A1 Substituted 2-phenyl-pyridine derivatives |
| 02/02/2011 | EP2279188A1 Purine pi3k inhibitor compounds and methods of use |
| 02/02/2011 | EP2279187A1 Spirocyclic derivatives as histone deacetylase inhibitors |
| 02/02/2011 | EP2279184A1 Indole modulators of the alpha-7 nicotinic acetylcholine receptor |
| 02/02/2011 | EP2279183A1 Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7 |
| 02/02/2011 | EP2279180A1 PROCESS FOR PREPARING A CRYSTALLINE FORM COMPOUND OF 3-BENZYL-2-METHYL-2,3,3a,4,5,6,7,7a-OCTAHYDROBENZOÝd¨ISOXAZOL-4-ONE |
| 02/02/2011 | EP2279179A2 Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof |
| 02/02/2011 | EP2279177A1 Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 02/02/2011 | EP2279174A2 Arylsulfonamide compounds, compositions and methods of use |
| 02/02/2011 | EP2279173A1 New arylsulphonylglycine derivatives, the preparation thereof and their use as medicaments |
| 02/02/2011 | EP2279169A2 Therapeutic compounds |
| 02/02/2011 | EP2279167A1 NOVEL PROCESS FOR THE PREPARATION OF 4-FLUORO-ALPHA-Ý2-METHYL -1-OXOPROPYL¨-GAMMA-OXO-N-ß-DIPHENYLBENZENEBUTANAMIDE AND PRODUCTS THEREFROM |
| 02/02/2011 | EP2279166A1 Substituted phenoxybenzamides |
| 02/02/2011 | EP2279030A2 Method of modulating t cell-dependent immune responses |
| 02/02/2011 | EP2279029A2 Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator |
| 02/02/2011 | EP2279009A2 Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure |
| 02/02/2011 | EP2279008A1 Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
| 02/02/2011 | EP2279005A1 Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer |
| 02/02/2011 | EP2278992A2 Therapy for vitiligo |
| 02/02/2011 | EP2278979A2 Method of treating pneumoconiosis with oligodeoxynucleotides |
| 02/02/2011 | EP2278978A2 Non-hormonal steroid modulators of nf-kb for treatment of disease |
| 02/02/2011 | EP2278977A1 Aromatic heterocyclic fused indolobenzadiazepine hcv ns5b inhibitors |
| 02/02/2011 | EP2278976A1 2h-benzo[b][1,4]oxazin-3(4h)-one derivatives for use as stearoyl coa desaturase inhibitors |
| 02/02/2011 | EP2278975A1 Novel nitroso compounds as nitroxyl donors and methods of use thereof |
| 02/02/2011 | EP2278974A1 A composition for regulation cellular senescence comprising lysophosphatidic acid and inhibitor of adenylyl cyclase as active ingredients |
| 02/02/2011 | EP2278973A1 Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
| 02/02/2011 | EP2278972A1 Treatment for neurological and mental disorders |
| 02/02/2011 | EP2278971A1 Compositions for the treatment of vaginal infections with chronic inflammation |
| 02/02/2011 | EP2278969A2 Inhibitors of janus kinases |
| 02/02/2011 | EP2278967A1 Bis-quaternary pyridinium-aldoyime salts and treatment of exposure to cholinesterase inhibitors |
| 02/02/2011 | EP2278966A2 Treatment with opioid antagonists and mtor inhibitors |
| 02/02/2011 | EP2278965A2 Substituted pyrazolamides and the use thereof |
| 02/02/2011 | EP2278964A1 Use of lhrh antagonists at non-castrating doses |
| 02/02/2011 | EP2278963A2 Derivatives of taxol and closely related compounds |
| 02/02/2011 | EP2278962A1 Methods for the treatment of dermatological disorders |
| 02/02/2011 | EP2278961A2 Calcimimetic compound for use in the treatment of epithelial injury |
| 02/02/2011 | EP2278960A1 Dosing regimen for a selective sip1 receptor agonist |
| 02/02/2011 | EP2278956A1 Antiviral formulation |
| 02/02/2011 | EP2278947A1 Treatment of dysmenorrhea via transdermal administration of nonsteroidal anti-inflammatory drugs |
| 02/02/2011 | EP2278890A1 Compositions of phytosterols with enhanced bioavailability |
| 02/02/2011 | EP2278885A2 Lipid-containing compositions and methods of use thereof |
| 02/02/2011 | EP2278880A1 Steroid treatment for hot flashes |
| 02/02/2011 | EP2278879A2 Compounds, compositions and methods comprising oxadiazole derivatives |
| 02/02/2011 | EP2278878A1 2-aryl glycinamide derivatives |
| 02/02/2011 | EP2123277B1 Preventive or therapeutic agent for inflammatory bowel disease |
| 02/02/2011 | EP2089369B1 2,4 -pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases |
| 02/02/2011 | EP2032593B1 Amino derivatives of b-homoandrostanes and b-heteroandrostanes |
| 02/02/2011 | EP1951303B1 Therapy with anti-cd4 antibodies and radiation |
| 02/02/2011 | EP1933843B1 Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives |
| 02/02/2011 | EP1919463B9 Use of hif 1alfa modulators for treatment of cancer |
| 02/02/2011 | EP1664092B1 Macrocyclic inhibitors of hepatitis c virus ns3 serine protease |
| 02/02/2011 | EP1606265B1 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| 02/02/2011 | EP1567508B1 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same |
| 02/02/2011 | EP1485358B1 Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors |
| 02/02/2011 | EP1364212B1 Three hybrid assay system |
| 02/02/2011 | EP1288205B1 Novel phenylalanine derivatives |
| 02/02/2011 | EP1039893B1 Pharmaceutical compositions containing an omega-3 fatty acid oil |
| 02/02/2011 | CN201727759U Pravastatin sodium enteric-coated capsule |
| 02/02/2011 | CN1980655B Lipase inhibitor |
| 02/02/2011 | CN1965836B Oral solid formulation and its preparation method |
| 02/02/2011 | CN1942473B Process for producing pentacyclic taxane |
| 02/02/2011 | CN1942191B Pharmaceutical composition comprising a salt of mirtazapine |
| 02/02/2011 | CN1927195B Film agent comprising sodium gualenate using for eyes |
| 02/02/2011 | CN1899615B Preparation for the prophylaxis of restenose |